Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro. (December 2022)

• Record Type: Journal Article
• Authors: Hassam, Muhammad; Bashir, Muhammad Arslan; Shafi, Sarah; Zahra, Noor-ul-Ain; Khan, Kanwal; Jalal, Khurshid; Siddiqui, Hina; Uddin, Reaz
• Is Part Of: Computers in biology and medicine. Volume 151:Part A(2022)
• Publication Date: 2022-12
• Subjects: COVID-19 -- Mpro -- Synthetic compounds -- Virtual screening -- Molecular docking and simulation; Medicine -- Data processing -- Periodicals; Biology -- Data processing -- Periodicals; 610.285
• DOI: 10.1016/j.compbiomed.2022.106284
• Languages: English
• ISSNs: 0010-4825

Abstract

Abstract: The worldwide pandemic of coronavirus disease 2019 (COVID-19) along with the various newly discovered major SARS-CoV-2 variants, including B.1.1.7, B.1.351, and B.1.1.28, constitute the Variant of Concerns (VOC). It's difficult to keep these variants from spreading over the planet. As a result of these VOCs, the fifth wave has already begun in several countries. The rapid spread of VOCs is posing a serious threat to human civilization. There is currently no specific medicine available for the treatment of COVID-19. Here, we present the findings of methods that used a combination of structure-assisted drug design, virtual screening, and high-throughput screening to swiftly generate lead compounds against Mpro protein of SARs-CoV-2. Therapeutics, in addition to vaccinations, are an essential element of the healthcare response to COVID-19's persistent threat. In the current study, we designed the efficient compounds that may combat all emerging variants of SARs-CoV-2 by targeting the common Mpro protein. The present study was aimed to discover new compounds that may be proposed as new therapeutic agents to treat COVID-19 infection without any adverse effects. For this purpose, a computational-based virtual screening of 352 in-house synthesized compounds library was performed through molecular docking and Molecular Dynamics (MD) simulation approach. As a result, four novel potent compounds were successfully shortlisted by implementing certain pharmacological, physiological, and ADMET criteria i.e., compounds 3, 4, 21, and 22 . Furthermore, MD simulations were performed to evaluate the stability and dynamic behavior of these compounds with Mpro complex for about 30 ns. Eventually, compound 22 was found to be highly potent against Mpro protein and was further evaluated by applying 100 ns simulations. Our findings showed that these shortlisted compounds may have potency to treat the COVID-19 infection for which further experimental validation is proposed as part of a follow-up investigation. Graphical abstract: Image 1 Highlights: Lead compounds against SARs-CoV-2 Mpro protein were designed using structure-assisted drug design. Hypothesized potent compounds that may treat all emerging variants of SARs-CoV-2. A computational-based virtual screening of 352 in-house synthesized compounds library was performed. Compound 22 was found to be highly potent against Mpro protein.